UA107928C2 - Method of senility treatment - Google Patents

Method of senility treatment

Info

Publication number
UA107928C2
UA107928C2 UAA201113554A UAA201113554A UA107928C2 UA 107928 C2 UA107928 C2 UA 107928C2 UA A201113554 A UAA201113554 A UA A201113554A UA A201113554 A UAA201113554 A UA A201113554A UA 107928 C2 UA107928 C2 UA 107928C2
Authority
UA
Ukraine
Prior art keywords
elderly
provides
vitamin
senility
treatment
Prior art date
Application number
UAA201113554A
Other languages
English (en)
Ukrainian (uk)
Inventor
Marjanna Prins
Helenius Jan Kloosterboer
Original Assignee
Organext Res B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42016317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107928(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organext Res B V filed Critical Organext Res B V
Publication of UA107928C2 publication Critical patent/UA107928C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA201113554A 2009-08-24 2010-08-23 Method of senility treatment UA107928C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09168522A EP2289555A1 (en) 2009-08-24 2009-08-24 Method of treating frailty
PCT/NL2010/050524 WO2011025368A1 (en) 2009-08-24 2010-08-23 Method of treating frailty

Publications (1)

Publication Number Publication Date
UA107928C2 true UA107928C2 (en) 2015-03-10

Family

ID=42016317

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201113554A UA107928C2 (en) 2009-08-24 2010-08-23 Method of senility treatment

Country Status (23)

Country Link
US (1) US10543217B2 (ru)
EP (2) EP2289555A1 (ru)
JP (2) JP2013502457A (ru)
KR (1) KR20120053987A (ru)
CN (1) CN102421450B (ru)
AU (1) AU2010287043B2 (ru)
BR (1) BRPI1011567B1 (ru)
CA (1) CA2759815C (ru)
CL (1) CL2011002863A1 (ru)
CO (1) CO6460777A2 (ru)
DK (1) DK2470214T3 (ru)
ES (1) ES2425095T3 (ru)
IL (1) IL216456A (ru)
MX (1) MX2011011905A (ru)
MY (1) MY162621A (ru)
NZ (1) NZ596057A (ru)
PL (1) PL2470214T3 (ru)
PT (1) PT2470214E (ru)
RU (1) RU2635541C2 (ru)
SG (1) SG176135A1 (ru)
UA (1) UA107928C2 (ru)
WO (1) WO2011025368A1 (ru)
ZA (1) ZA201108056B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101970893B1 (ko) 2017-10-18 2019-04-19 동아대학교 산학협력단 노쇠 여부 스크리닝 장치
CN109364034B (zh) * 2018-11-26 2021-05-04 正大制药（青岛）有限公司 一种骨化三醇制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
FI934891L (fi) * 1991-05-06 1993-12-03 Procter & Gamble Kombinerade kalcium- och vitamin d-supplement
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US7261905B2 (en) * 1999-04-07 2007-08-28 Pure Bioscience Disinfectant and method of making
US6638239B1 (en) * 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
GB0307728D0 (en) 2003-04-03 2003-05-07 Tesla Engineering Ltd Coil structure for magnetic resonance imaging
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
FR2860236B1 (fr) * 2003-09-25 2006-01-06 Theraptosis Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique
EP1896134A2 (en) * 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
SI3095447T1 (sl) * 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
CA2558202A1 (en) * 2006-09-14 2006-11-23 Reinhold W. Vieth Vitamin d compositions and method of administration to infants
RU2363488C1 (ru) * 2007-11-26 2009-08-10 Закрытое акционерное общество "Эксесс Байосаинс" Фармацевтическая композиция на основе пептида, регулирующего нарушения ангиогенеза, и способ ее применения
US9259430B2 (en) * 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf

Also Published As

Publication number Publication date
EP2470214B1 (en) 2013-05-15
IL216456A0 (en) 2012-01-31
ZA201108056B (en) 2012-07-25
EP2470214A1 (en) 2012-07-04
CL2011002863A1 (es) 2012-04-13
PT2470214E (pt) 2013-08-27
JP2013502457A (ja) 2013-01-24
CO6460777A2 (es) 2012-06-15
BRPI1011567A2 (pt) 2016-04-05
JP6279529B2 (ja) 2018-02-14
AU2010287043B2 (en) 2014-11-06
RU2635541C2 (ru) 2017-11-13
RU2011146830A (ru) 2013-10-10
US20120196837A1 (en) 2012-08-02
ES2425095T3 (es) 2013-10-11
AU2010287043A1 (en) 2011-11-10
KR20120053987A (ko) 2012-05-29
DK2470214T3 (da) 2013-08-12
NZ596057A (en) 2013-07-26
CA2759815C (en) 2018-06-12
PL2470214T3 (pl) 2013-12-31
IL216456A (en) 2017-04-30
MY162621A (en) 2017-06-30
JP2016011313A (ja) 2016-01-21
CA2759815A1 (en) 2011-03-03
US10543217B2 (en) 2020-01-28
MX2011011905A (es) 2012-01-30
EP2289555A1 (en) 2011-03-02
WO2011025368A1 (en) 2011-03-03
SG176135A1 (en) 2011-12-29
CN102421450A (zh) 2012-04-18
CN102421450B (zh) 2015-09-09
BRPI1011567B1 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
EP2392363A3 (en) Drug coated expandable devices
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
UA107928C2 (en) Method of senility treatment
MX344112B (es) Metodo y dispositivo para el tratamiento de trastornos del colesterol en la sangre.
So et al. Effect of compression bandaging on wound healing and psychosocial outcomes in older people with venous ulcers: a randomized controlled trial
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
Kmietowicz Geriatrician questions prescribing for stroke prevention in people over 80
Kocakaya et al. Ziprasidone Associated Sexual Hyperarousal: A Case Report
Noetzli Vascular events: case report
Hsieh et al. C24 SEDATION, DELIRIUM, AND NEUROCOGNITIVE DYSFUNCTION IN CRITICAL CARE: Feasibility And Efficacy Of Intranasal Insulin For Post-Operative Delirium: The Cns-Elders Randomized Controlled Trial
Su Cyclophosphamide/rituximab
Yazici Sialorrhoea: case report
Song et al. Clinical application of tinnitus retraining therapy on subjective tinnitus
Deriaz et al. P03-224 Melatonin in treatment of chronic sleep disorders in adults with pervasive development disorders: A retrospective study
Weintrub H1N1 Update: Oseltamivir Resistance and Antiviral Use
Wang Haemorrhagic cystitis: 23 case reports
Martinovic P01-118 Hepatitis C and depression-the effects of tianeptine
TH146677A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยแอนาบอลิค สเตอรอยด์ และสารประกอบวิตามิน d สำหรับใช้ในการผลิตยาเพื่อบำบัดความอ่อนแอ
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности